EGFR and non-small cell lung carcinoma: For instance, MPE-derived NSCLC cell lines with EGFR mutations such as SNU-2556, SNU-2643, SNU-2708.1, SNU-2741, SNU2867, SNU-2887, SNU-2964 and SNU-3023 as well as EGFR inhibitors including gefitinib, erlotinib and dacomitinib were tightly clustered together.